Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy

被引:1
作者
Vogelgesang, S
Kunert-Keil, C
Cascorbi, I
Mosyagin, I
Schröder, E
Runge, U
Jedlitschky, G
Kroemer, HK
Oertel, J
Gaab, MR
Pahnke, J
Walker, LC
Warzok, RW
机构
[1] Univ Greifswald, Dept Neuropathol, D-17487 Greifswald, Germany
[2] Univ Greifswald, Dept Pharmacol, D-17487 Greifswald, Germany
[3] Univ Greifswald, Dept Clin Neurol, D-17487 Greifswald, Germany
[4] Univ Hannover, Clin Neurosurg, Hannover, Germany
[5] Univ Zurich, Dept Neuropathol, Zurich, Switzerland
[6] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA
关键词
P-glycoprotein; MRP2; MRP5; BCRP; dysembryoplastic neuroepithelial tumor; epilepsy;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Dysembryoplastic neuroepithelial tumors (DNT) are relatively benign brain lesions that often cause medically intractable epilepsy. There is mounting evidence that multidrug transporters such as P-glycoprotein (P-gp) or multidrug resistance-associated proteins (MRP) play an important role in the development of resistance to antiepileptic drugs (AED). Material and methods: In the present study, we examined the expression of several multidrug transporters in 14 cases of DNT. The peritumoral brain tissue as well as 9 cases of arteriovenous malformations (AVM) served as controls. P-gp, MRP2, MRP5 and breast cancer resistance protein (BCRP) expression was evaluated qualitatively and quantitatively using immunohistochemistry. Results: All transporters were overexpressed quantitatively in DNT, but each revealed a different labeling pattern. P-gp and BCRP were predominantly located in the endothelium of brain vessels. MRP5 was detected primarily in endothelial cells, but notably also in neurons. The expression of P-gp, MRP2 and MRP5 was low in AVM whereas BCRP demonstrated strong staining. Examination of MDR1 gene polymorphisms revealed no correlation with P-gp expression whereas the MRP2 exon 10 G1249A polymorphism was associated with different MRP2 labelling. Conclusions: Our results show that multidrug transporters are overexpressed in DNT. This finding supports the view that several of these transport proteins may play an important role in the mechanisms of drug resistance in epileptic brain tissue.
引用
收藏
页码:223 / 231
页数:9
相关论文
共 39 条
  • [1] Pharmacogenetics of the human drug-transporter gene MDR1:: impact of polymorphisms on pharmacotherapy
    Brinkmann, U
    Roots, I
    Eichelbaum, M
    [J]. DRUG DISCOVERY TODAY, 2001, 6 (16) : 835 - 839
  • [2] Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
    Cascorbi, I
    Gerloff, T
    Johne, A
    Meisel, C
    Hoffmeyer, S
    Schwab, M
    Schaeffeler, E
    Eichelbaum, M
    Brinkmann, U
    Roots, I
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 169 - 174
  • [3] Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants
    Cox, DS
    Scott, KR
    Gao, HL
    Raje, S
    Eddington, ND
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (10) : 1540 - 1552
  • [4] Daumas-Duport C, 2000, PATHOLOGY GENETICS T, P103
  • [5] Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart
    Dazert, P
    Meissner, K
    Vogelgesang, S
    Heydrich, B
    Eckel, L
    Böhm, M
    Warzok, R
    Kerb, R
    Brinkmann, U
    Schaeffeler, E
    Schwab, M
    Cascorbi, I
    Jedlitschky, G
    Kroemer, HK
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (04) : 1567 - 1577
  • [6] Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy
    Dombrowski, SM
    Desai, SY
    Marroni, M
    Cucullo, L
    Goodrich, K
    Bingaman, W
    Mayberg, MR
    Bengez, L
    Janigro, D
    [J]. EPILEPSIA, 2001, 42 (12) : 1501 - 1506
  • [7] A new multidrug resistance protein at the blood-brain barrier
    Eisenblätter, T
    Galla, HJ
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (04) : 1273 - 1278
  • [8] The effect of rifampin treatment on intestinal expression of human MRP transporters
    Fromm, MF
    Kauffmann, HM
    Fritz, P
    Burk, O
    Kroemer, HK
    Warzok, RW
    Eichelbaum, M
    Siegmund, W
    Schrenk, D
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (05) : 1575 - 1580
  • [9] Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil
    Gramatté, T
    Oertel, R
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (03) : 239 - 245
  • [10] The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
    Greiner, B
    Eichelbaum, M
    Fritz, P
    Kreichgauer, HP
    Von Richter, O
    Zundler, J
    Kroemer, HK
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) : 147 - 153